Crimson Publishers Publish With Us Reprints e-Books Video articles


Global Journal of Endocrinological Metabolism

Molecular Pathways of, and the Future Therapeutic Implications for Atopic Dermatitis: A Review

  • Open or CloseASM Giasuddin1*, Shafiqul Islam2, Khadija Akther Jhuma3 and AM Mujibul Haq4

    1 Department of Biochemistry & Immunology, Medical Research Unit (MRU), Bangladesh

    2 Department of Dermatology, Medical College for Women & Hospital Member Secretary, Medical Research (MRU), Bangladesh

    3 Department of Biochemistry, Medical College for Women & Hospital Member Secretary, Medical Research Unit (MRU), Bangladesh

    4 Department of Medicine, Medical College for Women & Hospital Founder Principal & Chairman Projects, MHWT Chairman, Medical Research Unit (MRU), Bangladesh

    *Corresponding author:ASM Giasuddin, Department of Biochemistry & Immunology, Medical Research Unit (MRU), Bangladesh

Submission: Arpril 02, 2019 Published: April 09, 2019

DOI: 10.31031/GJEM.2019.03.000553

ISSN 2637-8019
Volume3 Issue1


No available treatments can provide long-term remission for patients with moderate to severe Atopic Dermatitis (AD) creating a large unmet need for effective systemic treatment. The important factors and related mechanisms for AD are the following:

a) Genetic

b) Neurohumoral

c) Skin barrier dysfunction and

d) Immunological mechanisms

The cellular interactions, molecular events and pathways for the pathogenesis of AD was integrated into a hypothesis and reported recently. As the new insights into the immune and molecular pathways of AD increase, a variety of experimental agents, particularly biological agents that target pathogenic molecules bring promise of safe and effective therapeutics. Some of the most promising biological therapies that are in development or in clinical trials are based on principles as the following: Barrier repair, Allergen specific immunotherapy, Targeted Immunomodulating Therapies (TIT) (Anti-IgE therapy, Anti-CD20, Inhibition of T-cell responses, Th2-cell inhibition strategies/ Anti IL-4 therapies, Anti IL-5 strategies, Anti IL-31), Targeting Th22, Targeting Th17/IL-12/IL-23 pathway, Recombinant IFN-y, Anti IL-6R, Anti TNF agents, Phosphodiesterase inhibitors, PPAR-gamma agonists.

All these biological therapies are at different phases of clinical trials. These biological agents would potentially hold great promise for the treatment of AD if they can offer advantages, i.e. low toxicity, good efficacy, improved patient compliance via given weekly/biweekly/and even monthly administration, reduction of disease activity, relapse prevention, etc. In Summary, the recent advances in understanding of the immunopathogenic mechanisms provide an opportunity for development of biological therapies directed at pathways driving AD. This is possibly the beginning of an exciting era in AD therapeutics with impending availability of drugs having low toxicity and increased patients’ compliance. These expected drugs will not only treat this disease, but also prevent the development and relapse of new skin lesions. In this article, attempts have been made to provide an updated account of these new possibilities.

Keywords: Atopic dermatitis; Eczema; Biologics; Therapeutics; Cytokines; Anti-cytokines

Get access to the full text of this article